In this episode of Galaxy Balance, Cory Smith speaks with Dr. Jonathan Scheiman, co-founder and CEO of FitBiomics, about the science of elite performance, microbiome discovery, and the future of metabolic health.

Jonathan shares his journey from Division I basketball player to biomedicine PhD and postdoctoral researcher in the Church Lab, where unconventional ideas are encouraged and ambitious biology is the norm

His central question was simple but radical: instead of studying disease, what if we studied peak human performance?

That question led to a longitudinal study of Boston Marathon runners, where his team collected microbiome samples before and after intense endurance events. The data revealed a striking pattern. One microorganism, Veillonella, spiked in abundance immediately after the marathon

Further analysis showed that this microbe uniquely metabolizes lactate and converts it into short-chain fatty acids such as propionate

Lactate is often misunderstood as a fatigue molecule. In reality, it is a normal metabolic fuel. When produced in excess during intense exercise, it accumulates in the bloodstream. Scheiman’s work suggests that a portion of circulating lactate is shuttled to the gut, where Veillonella uses it as a carbon source, producing metabolites that may support mitochondrial function, muscle recovery, glucose utilization, and anti-inflammatory pathways

The episode explores:

• How elite athletes may represent a rare biological phenotype comparable in rarity to centenarians
• Why the microbiome can shift rapidly in response to exercise intensity
• The challenges of culturing and scaling strict anaerobic microbes for commercialization
• The regulatory pathway differences between therapeutic microbiome interventions and consumer health products
• How AI and machine learning enabled the discovery of novel microbial signals in complex datasets

The conversation expands into longevity, mitochondrial efficiency, digital health integration, and the idea of FitBiomics as a biological data company rather than simply a probiotic brand

Scheiman also reflects on science fiction, pop culture, and storytelling as forces that shape technological ambition, drawing connections between Marvel, AI, and biotechnology innovation

This episode sits at the intersection of microbiome science, metabolic optimization, artificial intelligence, and the long-term future of human performance.

If the biology of elite athletes can be decoded and translated, the implications extend far beyond sport.

00:00 - Introduction to microbiome insights for human performance
02:20 - Personal journey from sports to biotech innovation
05:28 - How elite athletes inspired microbiome research
09:04 - Approaching human performance limits and societal health impacts
13:48 - Early discoveries: microbiome sampling from Boston Marathon runners
27:19 - The breakthrough finding: Vianella's role in fatigue and endurance
30:19 - Scientific steps to isolate and validate Vianella
33:29 - Regulatory considerations for microbiome supplements versus therapeutics
36:04 - Prevalence of Vianella across different athletes and individuals
40:51 - Microbiome as a dynamic, modifiable biomarker for health and sport
45:37 - Metabolism, mitochondria, and longevity interconnected through microbiome dynamics
49:16 - Influences of science fiction on biotech imagination and vision
57:39 - Future applications: wearables, continuous monitoring, and AI in microbiome health
1:00:46 - Vision for FitBiomics’ role in health innovation and societal impact